Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.07.23	Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease (GlobeNewswire)
07.06.23	Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce neuroinflammation (GlobeNewswire)
16.05.23	Karolinska Development’s Annual General Meeting 2023 (GlobeNewswire)
12.05.23	Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia (GlobeNewswire)
28.04.23	Interim Report - January-March 2023 (GlobeNewswire)
17.04.23	Karolinska Development’s portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis (GlobeNewswire)
13.04.23	Karolinska Development’s portfolio company AnaCardio recruits first patient to a clinical trial of its drug candidate AC01 (GlobeNewswire)
11.04.23	Notice of Annual General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
28.03.23	Karolinska Development’s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone (GlobeNewswire)
24.03.23	Karolinska Development Annual Report 2022 published (GlobeNewswire)
14.03.23	Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01 (GlobeNewswire)
13.03.23	Karolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal infection (GlobeNewswire)
28.02.23	Karolinska Development’s portfolio company SVF Vaccines initiates clinical phase 1 study of its universal Covid-19 vaccine (GlobeNewswire)
28.02.23	Karolinska Development’s portfolio company Aprea Therapeutics secures funding of USD 5.5 million (GlobeNewswire)
21.02.23	Karolinska Development’s portfolio company Modus Therapeutics presents positive results from a clinical trial of sevuparin (GlobeNewswire)
17.02.23	Year-end Report - January-December 2022 (GlobeNewswire)
14.02.23	Karolinska Development’s portfolio company Dilafor reports maintained effect in the extension study of tafoxiparin (GlobeNewswire)
18.11.22	Interim Report - January-September 2022 (GlobeNewswire)
19.08.22	Interim Report - January-June 2022 (GlobeNewswire)
22.07.22	Karolinska Developments portfolio company Promimic and Danco Medical form a joint venture for the US-market (GlobeNewswire)
04.07.22	Karolinska Development expands its portfolio following an investment in PharmNovo (GlobeNewswire)
27.06.22	Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference (GlobeNewswire)
23.06.22	Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants (GlobeNewswire)
03.06.22	Karolinska Development invests in breakthrough drug project for the treatment of nerve pain (GlobeNewswire)
19.05.22	Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten